THERAPEUTICS
Citalopram-resistant depression: cognitive therapy and medication similarly effective as second line treatments
| The first 150 words of the full text of this article appear below. |
Dr Thase
Correspondence to: Dr Thase, University of Pittsburgh Medical Center, 3811 OHara Street, Pittsburgh, PA 15213-2593, USA; thaseme@upmc.edu
Cognitive therapy or pharmacotherapy as second-line for people with citalopram-resistant depression—which is more effective?
304 out-patients with non-psychotic major depressive disorder (clinically established diagnosis verified through DSM-IV criteria) enrolled in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study who did not achieve remission (remission defined as Quick Inventory of Depressive Symptomatology score
5) with first-line citalopram treatment. This analysis included only those people who agreed to be randomised to treatment strategies (augmentations, switches or both) which would allow cognitive therapy to be compared with pharmacotherapy.
Primary care and psychiatric care practice settings across the USA; recruitment July 2001 to April 2004.
Participants who did not achieve remission were randomised to one of seven second-line treatments: ongoing citalopram with sustained-release bupropion, buspirone, or cognitive therapy (augmentation strategies; n = 182); or
University Health Network and University of Toronto, Toronto, Canada
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
